There may never be a vaccine.
A vaccine may apparently be developed but long term effects will be unknown.
The most plausible scenario is that there may be promising vaccine available for mass usage, and with a reasonable level of safety, in the summer of 2021.
RAPS has an illuminating post detailing the various vaccines under trial and their status:
Researchers worldwide are working around the clock to find a vaccine against SARS-CoV-2, the virus causing the COVID-19 pandemic. Experts estimate that a fast-tracked vaccine development process could speed a successful candidate to market in approximately 12-18 months – if the process goes smoothly from conception to market availability.
To date, just one coronavirus vaccine has been approved. Sputnik V – formerly known as Gam-COVID-Vac and developed by the Gamaleya Research Institute in Moscow – was approved by the Ministry of Health of the Russian Federation on 11 August. ……….
The pandemic has created unprecedented public/private partnerships. Operation Warp Speed (OWS) is a collaboration of several US federal government departments including Health and Human Services and its subagencies, Agriculture, Energy and Veterans Affairs and the private sector. Within OWS, the US National Institutes of Health (NIH) has partnered with more than 18 biopharmaceutical companies to accelerate development of drug and vaccine candidates for COVID-19 (ACTIV). The COVID-19 Prevention Trials Network (COVPN) has also been established, which combines clinical trial networks funded by the National Institute of Allergy and Infectious Diseases (NIAID): the HIV Vaccine Trials Network (HVTN), HIV Prevention Trials Network (HPTN), Infectious Diseases Clinical Research Consortium (IDCRC), and the AIDS Clinical Trials Group.
The COVAX initiative, part of the World Health Organization’s (WHO) Access to COVID-19 Tools (ACT) Accelerator, is being spearheaded by the Coalition for Epidemic Preparedness Innovations (CEPI); Gavi, the Vaccine Alliance; and WHO. The goal is to work with vaccine manufacturers to offer low-cost COVID-19 vaccines to countries. Currently, CEPI’s candidates from companies Inovio, Moderna, CureVac, Institut Pasteur/Merck/Themis, AstraZeneca/University of Oxford, Novavax, University of Hong Kong, Clover Biopharmaceuticals, and University of Queensland/CSL are part of the COVAX initiative. There are further candidates being evaluated in the COVAX Facility from the United States and internationally.
The US government has chosen three vaccine candidates to fund for Phase 3 trials under Operation Warp Speed: Moderna’s mRNA-1273, The University of Oxford and AstraZeneca’s AZD1222, and Pfizer and BioNTech’s BNT162. Members of ACTIV have suggested developing safe controlled human infection models (CHIMs) for human trials could take 1-2 years. A sponsor would need to provide data from placebo-controlled trials indicating their vaccine is at least 50% effective against COVID-19 in order to be authorized for use, according to FDA guidance issued and effective 30 June.
The 44 candidates ( as of 31st August 2020) are:
AAVCOVID, Ad26.COV2-S, Ad5-nCoV, AdCOVID, Adenovirus-based vaccine, AdimrSC-2f, Adjuvant recombinant vaccine candidate, AZD1222/Covishield, Bacillus Calmette-Guerin (BCG) live-attenuated vaccine, bacTRL-Spike, BBIBP-CorV, BNT162, ChAd-SARS-CoV-2-S, CoronaVac, COVAX-19, Covaxin, gp96-based vaccine, GRAd-COV2, GRAd-COV2, HaloVax, HDT-301, Ii-Key peptide COVID-19 vaccine, Inactivated vaccine, INO-4800, LineaDNA, LUNAR-COV19, Molecular clamp vaccine, mRNA lipid nanoparticle (mRNA-LNP) vaccine, mRNA-1273, mRNA-based vaccine, mRNA-based vaccine, NVX-CoV2373, PittCoVacc, Plant-based adjutant COVID-19 vaccine candidate, Protein subunit vaccine, Recombinant vaccine 1, Recombinant vaccine 2, SCB-2019, Self-amplifying RNA vaccine, Sputnik V, T-COVIDTM, V590, V591, ZyCoV-D
Covid candidate vaccines (pdf)
Tags: coronavirus, covid-19
The k2p blog 